NEW HAVEN, Conn.–(BUSINESS WIRE)–#Rallybio–Rallybio, a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that it has appointed Helen M. Boudreau, former Chief Operating Officer of the Bill & Melinda Gates Medical Research Institute, to its Board of Directors. Ms. Boudreau will also serve as Chair of the Audit Committee.
“Helen will add significant value as a Rallybio board member, drawing on her more than 30 years of executive leadership experience in finance, corporate strategy, global commercial operations, and R&D portfolio management,” said Rallybio co-founder, Dr. Martin Mackay. “Her executive experience in the pharmaceutical and biopharma industry further strengthens our board and we look forward to benefiting from her expertise as we continue to grow our Company.”
“I’m excited to join Rallybio’s Board, and to contribute to the Company’s mission,” said Ms. Boudreau. “I look forward to collaborating with my fellow Board members and the Rallybio leadership team as we advance Rallybio’s portfolio of potentially life-transforming candidates with the goal of having a meaningful impact on the lives of patients in need.”
Ms. Boudreau brings extensive experience to the Board from across the biotech, pharmaceutical, consulting, and banking industries. At the Bill & Melinda Gates Medical Research Institute, she led operations for a newly created translational medicine biotech non-profit. She previously served as the Chief Financial Officer for Proteostasis Therapeutics (NASDAQ: PTI) and FORMA Therapeutics. Prior to that, Ms. Boudreau held positions of increasing scope and responsibility in the pharmaceutical industry, including Chief Financial Officer of Novartis Corporation US. Ms. Boudreau started her career in banking and was also an engagement manager at McKinsey & Company. Ms. Boudreau currently serves on the Board of Premier Inc. (NASDAQ: PINC), a healthcare improvement company, and three private biotechnology companies. She earned an MBA from the Darden Graduate School of Business Administration, University of Virginia, and a BA in Economics, summa cum laude, from the University of Maryland.
Rallybio is a biopharmaceutical company focused on identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, and metabolism. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.
Laura Ekas, PhD